ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is…
An institutional-grade, numbers-driven thesis on ABVC — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of July 4, 2026, TradersQuant's model rates ABVC BioPharma, Inc. (ABVC) 52/100 with a 12-month base-case forecast of $1.53 — -15.0% versus the current price of $1.80. ABVC BioPharma, Inc. trades at $1.80 in the Healthcare sector, with a market capitalisation of $26.1M. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month TradersQuant model price target for ABVC is $1.53, implying -15.0% versus the current price. The model's 12-month scenario range runs from $1.38 (bear) to $1.74 (bull), with a base case of $1.53.
On the fundamentals, ABVC BioPharma shows a P/E of -4.9, trailing revenue of $509589, revenue growth of -100.0% YoY. This page also tracks ABVC's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
ABVC currently carries a TradersQuant composite score of 52/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "Hold". Our 12-month price target of $1.53 implies -15.0% from $1.80. This is research, not financial advice — always combine it with your own judgement.
The TradersQuant 12-month model price target for ABVC is $1.53, about -15.0% versus the latest price of $1.80. Consensus is based on 1 analysts.
TradersQuant's 12-month model forecast for ABVC is a base case of $1.53, ranging from $1.38 (bear) to $1.74 (bull), an expected return of -15.2%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for ABVC over the next 12 months is $1.53 in the base case (bear $1.38, bull $1.74), versus today's price of $1.80. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for ABVC — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates ABVC's fair value at $2.27, implying +26.0% of expected upside versus the current price.
ABVC BioPharma does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
